Mesoblast (NASDAQ:MESO) Stock Price Up 4.8% – Should You Buy?

Mesoblast Limited (NASDAQ:MESO)’s stock price shot up 4.8% during mid-day trading on Wednesday . The stock traded as high as $19.50 and last traded at $19.19. 74,293 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 471,268 shares. The stock had previously closed at $18.32.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Piper Sandler boosted their price objective on shares of Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a report on Thursday, December 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Mesoblast presently has an average rating of “Hold” and an average target price of $13.50.

Mesoblast Price Performance

The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The business has a 50-day moving average price of $15.47 and a two-hundred day moving average price of $10.49.

Institutional Investors Weigh In On Mesoblast

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new stake in shares of Mesoblast during the second quarter worth about $562,000. Perkins Coie Trust Co boosted its position in Mesoblast by 15.0% during the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after acquiring an additional 1,500 shares during the last quarter. Creative Planning purchased a new stake in Mesoblast in the 3rd quarter worth approximately $147,000. Signaturefd LLC raised its holdings in Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after acquiring an additional 3,099 shares during the last quarter. Finally, XY Capital Ltd purchased a new position in shares of Mesoblast during the 3rd quarter worth $244,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.